ID   L-540
AC   CVCL_1362
SY   L 540; L540
DR   BTO; BTO:0005176
DR   CLO; CLO_0007201
DR   CLDB; cl455
DR   ArrayExpress; E-MTAB-783
DR   ArrayExpress; E-MTAB-2770
DR   ArrayExpress; E-MTAB-3610
DR   BioSample; SAMN03473399
DR   BioSample; SAMN10988507
DR   cancercelllines; CVCL_1362
DR   Cell_Model_Passport; SIDM00329
DR   ChEMBL-Cells; CHEMBL3308531
DR   ChEMBL-Targets; CHEMBL2366153
DR   CLS; 300201
DR   Cosmic; 907323
DR   Cosmic; 988705
DR   Cosmic; 1013911
DR   Cosmic; 1086359
DR   Cosmic; 1432039
DR   Cosmic; 2276327
DR   Cosmic; 2464307
DR   Cosmic-CLP; 907323
DR   DepMap; ACH-000806
DR   DSMZ; ACC-72
DR   DSMZCellDive; ACC-72
DR   EGA; EGAS00001000978
DR   GDSC; 907323
DR   GEO; GSM335392
DR   GEO; GSM499725
DR   GEO; GSM499726
DR   GEO; GSM552448
DR   GEO; GSM646532
DR   GEO; GSM646535
DR   GEO; GSM887261
DR   GEO; GSM888336
DR   GEO; GSM1670030
DR   IARC_TP53; 21456
DR   IARC_TP53; 23615
DR   LiGeA; CCLE_220
DR   LINCS_LDP; LCL-2012
DR   PharmacoDB; L540_816_2019
DR   PRIDE; PXD000589
DR   PRIDE; PXD030304
DR   Progenetix; CVCL_1362
DR   PubChem_Cell_line; CVCL_1362
DR   Wikidata; Q54900876
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RX   PubMed=2690233;
RX   PubMed=6303739;
RX   PubMed=6305805;
RX   PubMed=7276066;
RX   PubMed=7530238;
RX   PubMed=8558920;
RX   PubMed=11021758;
RX   PubMed=12581897;
RX   PubMed=17065008;
RX   PubMed=20164919;
RX   PubMed=20628145;
RX   PubMed=22460905;
RX   PubMed=25355872;
RX   PubMed=25894527;
RX   PubMed=26589293;
RX   PubMed=27397505;
RX   PubMed=29533902;
RX   PubMed=30285677;
RX   PubMed=30629668;
RX   PubMed=30894373;
RX   PubMed=31068700;
RX   PubMed=35839778;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Population: Caucasian.
CC   Doubling time: ~70 hours (DSMZ=ACC-72).
CC   HLA typing: A*03:01,11:01; B*51:01,51:01; C*02:02,15:02; DQA1*03:02,05:01; DQB1*03:03,03:03; DRB1*04:04,11:01 (PubMed=26589293).
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Transformant: NCBI_TaxID; 10376; Epstein-Barr virus (EBV).
CC   Omics: Cell surface proteome.
CC   Omics: Deep exome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Omics: Virome analysis using RNAseq.
CC   Genome ancestry: African=0%; Native American=0%; East Asian, North=1.11%; East Asian, South=0.61%; South Asian=0.05%; European, North=70.77%; European, South=27.46% (PubMed=30894373).
CC   Derived from site: In situ; Bone marrow; UBERON=UBERON_0002371.
ST   Source(s): Cosmic-CLP; DSMZ
ST   Amelogenin: X
ST   CSF1PO: 11,13
ST   D13S317: 9
ST   D16S539: 11,13
ST   D18S51: 18
ST   D19S433: 13,14
ST   D21S11: 29,30
ST   D2S1338: 20,21
ST   D3S1358: 16,17
ST   D5S818: 11,13
ST   D7S820: 11,12
ST   D8S1179: 11,14
ST   FGA: 21,24
ST   Penta D: 9,10
ST   Penta E: 12
ST   TH01: 7,9
ST   TPOX: 9,10
ST   vWA: 17,18
DI   NCIt; C9357; Hodgkin lymphoma
DI   ORDO; Orphanet_98293; Hodgkin lymphoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_M700 ! L-538
SX   Female
AG   20Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 38
//
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RA   Drexler H.G.;
RT   "The leukemia-lymphoma cell line factsbook.";
RL   (In) ISBN 9780122219702; pp.1-733; Academic Press; London (2001).
//
RX   PubMed=2690233; DOI=10.1007/978-3-642-83781-4_5;
RA   Schaadt M., Burrichter H., Pfreundschuh M., Schell-Frederick E.,
RA   Tesch H., Fonatsch C., Stein H., Diehl V.;
RT   "Biology of Hodgkin cell lines.";
RL   Recent Results Cancer Res. 117:53-61(1989).
//
RX   PubMed=6303739; DOI=10.1055/s-2008-1069671;
RA   Kirchner H.H., Burrichter H., Stein H., Fonatsch C., Schaadt M.,
RA   Ziegler A., Heit W., Diehl V.;
RT   "Properties of Hodgkin cell lines. Possible significance for
RT   pathophysiology and clinical medicine.";
RL   Dtsch. Med. Wochenschr. 108:936-944(1983).
//
RX   PubMed=6305805; DOI=10.1007/978-3-642-68761-7_81;
RA   Diehl V., Burrichter H., Schaadt M., Kirchner H.H., Fonatsch C.,
RA   Stein H., Gerdes J., Heit W., Ziegler A.;
RT   "Hodgkin's disease cell lines: characteristics and biological
RT   activities.";
RL   Haematol. Blood Transfus. 28:411-417(1983).
//
RX   PubMed=7276066; DOI=10.1007/BF00405072;
RA   Diehl V., Kirchner H.H., Schaadt M., Fonatsch C., Stein H., Gerdes J.,
RA   Boie C.;
RT   "Hodgkin's disease: establishment and characterization of four in
RT   vitro cell lines.";
RL   J. Cancer Res. Clin. Oncol. 101:111-124(1981).
//
RX   PubMed=7530238; DOI=10.1002/ijc.2910600419;
RA   Horn-Lohrens O., Tiemann M., Lange H., Kobarg J., Hafner M.,
RA   Hansen H., Sterry W., Parwaresch M.R., Lemke H.;
RT   "Shedding of the soluble form of CD30 from the Hodgkin-analogous cell
RT   line L540 is strongly inhibited by a new CD30-specific antibody
RT   (Ki-4).";
RL   Int. J. Cancer 60:539-544(1995).
//
RX   PubMed=8558920;
RA   Dirks W.G., Zaborski M., Jager K., Challier C., Shiota M.,
RA   Quentmeier H., Drexler H.G.;
RT   "The (2;5)(p23;q35) translocation in cell lines derived from malignant
RT   lymphomas: absence of t(2;5) in Hodgkin-analogous cell lines.";
RL   Leukemia 10:142-149(1996).
//
RX   PubMed=11021758; DOI=10.1038/sj.leu.2401891;
RA   Majka M., Rozmyslowicz T., Honczarenko M., Ratajczak J., Wasik M.A.,
RA   Gaulton G.N., Ratajczak M.Z.;
RT   "Biological significance of the expression of HIV-related chemokine
RT   coreceptors (CCR5 and CXCR4) and their ligands by human hematopoietic
RT   cell lines.";
RL   Leukemia 14:1821-1832(2000).
//
RX   PubMed=12581897; DOI=10.1016/S0165-4608(02)00656-8;
RA   Berglund M., Flordal E., Gullander J., Lui W.-O., Larsson C.,
RA   Lagercrantz S., Enblad G.;
RT   "Molecular cytogenetic characterization of four commonly used cell
RT   lines derived from Hodgkin lymphoma.";
RL   Cancer Genet. Cytogenet. 141:43-48(2003).
//
RX   PubMed=17065008; DOI=10.1080/10428190600667721;
RA   Feuerborn A., Moritz C., von Bonin F., Dobbelstein M., Trumper L.,
RA   Sturzenhofecker B., Kube D.;
RT   "Dysfunctional p53 deletion mutants in cell lines derived from
RT   Hodgkin's lymphoma.";
RL   Leuk. Lymphoma 47:1932-1940(2006).
//
RX   PubMed=20164919; DOI=10.1038/nature08768;
RA   Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
//
RX   PubMed=20628145; DOI=10.1182/blood-2010-05-282780;
RA   Green M.R., Monti S., Rodig S.J., Juszczynski P., Currie T.,
RA   O'Donnell E., Chapuy B., Takeyama K., Neuberg D., Golub T.R.,
RA   Kutok J.L., Shipp M.A.;
RT   "Integrative analysis reveals selective 9p24.1 amplification,
RT   increased PD-1 ligand expression, and further induction via JAK2 in
RT   nodular sclerosing Hodgkin lymphoma and primary mediastinal large
RT   B-cell lymphoma.";
RL   Blood 116:3268-3277(2010).
//
RX   PubMed=22460905; DOI=10.1038/nature11003;
RA   Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A.,
RA   Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A.,
RA   Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J.,
RA   Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E.,
RA   Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J.,
RA   Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C.,
RA   Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C.,
RA   Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P.,
RA   Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L.,
RA   Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R.,
RA   Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.;
RT   "The Cancer Cell Line Encyclopedia enables predictive modelling of
RT   anticancer drug sensitivity.";
RL   Nature 483:603-607(2012).
//
RX   PubMed=25355872; DOI=10.1128/JVI.02570-14;
RA   Cao S.-B., Strong M.J., Wang X., Moss W.N., Concha M., Lin Z.,
RA   O'Grady T., Baddoo M., Fewell C., Renne R., Flemington E.K.;
RT   "High-throughput RNA sequencing-based virome analysis of 50 lymphoma
RT   cell lines from the Cancer Cell Line Encyclopedia project.";
RL   J. Virol. 89:713-729(2015).
//
RX   PubMed=25894527; DOI=10.1371/journal.pone.0121314;
RA   Bausch-Fluck D., Hofmann A., Bock T., Frei A.P., Cerciello F.,
RA   Jacobs A., Moest H., Omasits U., Gundry R.L., Yoon C., Schiess R.,
RA   Schmidt A., Mirkowska P., Hartlova A.S., Van Eyk J.E., Bourquin J.-P.,
RA   Aebersold R., Boheler K.R., Zandstra P.W., Wollscheid B.;
RT   "A mass spectrometric-derived cell surface protein atlas.";
RL   PLoS ONE 10:E0121314-E0121314(2015).
//
RX   PubMed=26589293; DOI=10.1186/s13073-015-0240-5;
RA   Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P.,
RA   Loewer M., Sahin U., Castle J.C.;
RT   "TCLP: an online cancer cell line catalogue integrating HLA type,
RT   predicted neo-epitopes, virus and gene expression.";
RL   Genome Med. 7:118.1-118.7(2015).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=29533902; DOI=10.1515/hsz-2017-0321;
RA   Drexler H.G., Pommerenke C., Eberth S., Nagel S.;
RT   "Hodgkin lymphoma cell lines: to separate the wheat from the chaff.";
RL   Biol. Chem. 399:511-523(2018).
//
RX   PubMed=30285677; DOI=10.1186/s12885-018-4840-5;
RA   Tan K.-T., Ding L.-W., Sun Q.-Y., Lao Z.-T., Chien W., Ren X.,
RA   Xiao J.-F., Loh X.-Y., Xu L., Lill M., Mayakonda A., Lin D.-C., Yang H.,
RA   Koeffler H.P.;
RT   "Profiling the B/T cell receptor repertoire of lymphocyte derived cell
RT   lines.";
RL   BMC Cancer 18:940.1-940.13(2018).
//
RX   PubMed=30629668; DOI=10.1371/journal.pone.0210404;
RA   Uphoff C.C., Pommerenke C., Denkmann S.A., Drexler H.G.;
RT   "Screening human cell lines for viral infections applying RNA-Seq data
RT   analysis.";
RL   PLoS ONE 14:E0210404-E0210404(2019).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).
//